A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008916
Abstract: To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n=50, 62%) or in combination with a BTK inhibitor (n=16, 20%), an anti-CD20… read more here.
Keywords: venetoclax patients; relapsed mantle; risk; analysis ... See more keywords